Welcome to our dedicated page for Innate Pharma Sa news (Ticker: IPHA), a resource for investors and traders seeking the latest updates and insights on Innate Pharma Sa stock.
Innate Pharma S.A. develops clinical-stage cancer immunotherapies based on antibody engineering and target identification. Company news commonly covers its next-generation antibody therapeutics portfolio, including IPH4502, a Nectin-4 antibody-drug conjugate for solid tumors; lacutamab, an anti-KIR3DL2 antibody for cutaneous and peripheral T-cell lymphomas; monalizumab, an anti-NKG2A antibody developed with AstraZeneca for non-small cell lung cancer; and IPH5201, an anti-CD39 antibody studied in non-small cell lung cancer.
Updates also address collaborations with biopharmaceutical partners such as Sanofi and AstraZeneca, oncology conference presentations, business updates, annual meeting matters, share-count and voting-right disclosures, and annual reporting under French and U.S. public-company requirements.
Innate Pharma (Nasdaq: IPHA) reported the voting results of its 2026 Annual General Meeting held on May 21, 2026, in Marseille.
According to Innate Pharma, shareholders cast 94 votes out of 34,872,293 shares representing 34,921,313 voting rights, for a stated quorum of 37,136%. AGM documentation and the meeting recording will be available on the company’s website.
Innate Pharma (Nasdaq:IPHA), a clinical-stage biotech focused on cancer immunotherapies, announced that its executive team will attend the Jefferies Global Healthcare Conference 2026.
Management will hold one-on-one investor meetings in New York from June 2–4, 2026, offering updates on the company and its pipeline.
Innate Pharma (Nasdaq: IPHA) reported Q1 2026 revenue of €2.6 million, up from €1.2 million a year earlier. Cash and financial assets were €25.4 million with an expected runway until end of Q3 2026, and financial liabilities of €20.3 million.
Key R&D updates include the planned H2 2026 start of the lacutamab TELLOMAK-3 Phase 3 CTCL trial, pending non‑dilutive financing, IPH4502 Phase 1 enrollment nearing completion with preliminary anti‑tumor activity, PACIFIC‑9 Phase 3 fully enrolled with an H2 2026 data readout, and encouraging MATISSE Phase 2 pCR data for IPH5201 in NSCLC. The company completed a redundancy plan with layoffs, while Sanofi deprioritized the partnered IPH6401/SAR’514 program; $75 million remains available under the ATM facility.
Innate Pharma (IPHA) reported its capital and voting structure as of April 16, 2026. The company has 93,934,210 shares outstanding, including 93,921,863 ordinary shares, 4,766 Preferred Shares 2016, and 7,581 Preferred Shares 2017.
There are 93,921,863 theoretical voting rights and 93,903,288 exercisable voting rights, with treasury shares excluded from net voting rights, in line with AMF regulations.
Innate Pharma (Nasdaq: IPHA) will hold a conference call and webcast on May 13, 2026 at 1:30 p.m. CEST / 7:30 a.m. EDT to provide a Q1 2026 business update. Management participants include CEO Jonathan Dickinson and CFO Frédéric Lombard.
The live webcast link and telephone registration are on the company website; a replay will be available for 90 days following the event.
Innate Pharma (Nasdaq: IPHA) said its executive team will hold one-on-one investor meetings at the D. Boral Capital Global Conference in New York on May 7, 2026. The meetings are scheduled as part of the conference's investor program and are intended for institutional engagement.
Innate Pharma (Nasdaq: IPHA) will present interim MATISSE Phase 2 results for IPH5201 plus durvalumab and platinum chemotherapy at AACR 2026 on April 21, 2026.
In a pre-planned interim analysis of 40 patients, pathological complete response (pCR) was 35.7% for PD-L1 ≥1% and 50% for PD-L1 ≥50%; enrollment continues in PD-L1 ≥1% patients.
Innate Pharma (Euronext: IPH; Nasdaq: IPHA) will hold its Annual General Meeting on May 21, 2026 at 10:30 a.m. CEST at its Marseille headquarters. The notice published April 13, 2026 includes the agenda, proposed resolutions and participation and voting instructions.
Documents and live broadcast will be available on the Investors section of the company's website. A guided laboratory tour for shareholders is scheduled at 9:15 a.m. CEST the same day. Registration, voting eligibility and written question deadlines are specified in the notice.
Innate Pharma (Euronext: IPH; Nasdaq: IPHA) reports its share count and voting rights as of April 9, 2026. Total shares outstanding are 93,860,680, comprising 93,847,763 ordinary shares, 5,336 preferred shares 2016, and 7,581 preferred shares 2017.
The total number of theoretical voting rights is 94,484,443 and the total number of exercisable voting rights is 94,465,868. AGAP 2016 instruments carry 130 and 111 voting rights respectively; AGAP 2017 carries no voting rights.
Innate Pharma (Nasdaq: IPHA) announced that COO Yannis Morel will present at the AACR Oncology Industry Partnering Event on April 16, 2026 in San Diego. The presentation is in Showcase Session 2 at 6:10 PM PDT and will highlight the company’s oncology pipeline, including IPH4502.
The session offers direct exposure to investors, analysts and industry partners and may support scientific and business engagement on Innate Pharma’s clinical programs.